Last reviewed · How we verify
NCT04861415: SHARP
SBRT vs. Conventional Fractionation With HDR Boost for Prostate Cancer
NA trial testing Sterotactic Body Radiotherapy in Prostate Cancer in 55 participants. Currently enrolling.
23 June 2023
Quick facts
| Lead sponsor | Dr. Gerard Morton |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 55 |
| Start date | 23 December 2020 |
| Primary completion | 23 June 2023 |
| Estimated completion | 23 December 2027 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Sterotactic Body Radiotherapy
- Conventionally Fractionated Radiation
Conditions studied
- Prostate Cancer — all drugs for Prostate Cancer →
Sponsor
Dr. Gerard Morton
Who can join
18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Random assignment between SBRT and conventionally fractionated boost following HDR brachytherapy for prostate cancer.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Stereotactic Body Radiotherapy: Hitting Harder, Faster, and Smarter in High-Risk Prostate Cancer.
Correa RJM, Loblaw A. · · 2022 · cited 14× · PMID 35875062 · DOI 10.3389/fonc.2022.889132 -
Review of brachytherapy clinical trials: a cross-sectional analysis of ClinicalTrials.gov.
Chen D, Parsa R, Chauhan K, Lukovic J, et al · · 2024 · cited 2× · PMID 38351013 · DOI 10.1186/s13014-024-02415-8
Verify or expand the search:
- PubMed search for NCT04861415
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Sterotactic Body Radiotherapy
Trials testing the same drug.
- NCT05614700 — Prostate Reirradiation Toxicity Outcomes Feasibility Study · NA · not yet recruiting
Other recruiting trials for Prostate Cancer
Currently open trials in the same condition.
- NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
- NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
- NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
- NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
- NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04861415 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Dr. Gerard Morton
- Last refreshed: 12 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04861415.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing